Latest Breaking News On - Pauline williams - Page 11 : comparemela.com

ng Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis (TB). 1 Lutz Hegemann, M.D., Chief Operating Officer for Global Health at Novartis said: “Novartis has a long-standing commitment to improving and extending the lives of patients around the world.  Our efforts include seeking innovative ways to improve the standard of care where possible. This is why we are excited by this important collaboration on scientific research on genetic diversity in Africa. It has the potential to improve the efficacy and tolerability of current and future medicines, starting with two of the most deadly diseases, malaria and tuberculosis. In alignment with our ongoing efforts to strengthen scientific capabilities in lower-resource settings, this project also provides opportunities

United statesIsabella zinckEric althoffThomas hungerbuehlerKara cournoyerGlenda graySamir shahLutz hegemannSloan simpsonKaterina kontzalisAntonio ligiPauline williamsNovartis global health corporate responsibilityGlobal health pharmaNovartis institutes for biomedical researchNovartis institutes for biomedical research on african